病毒性心肌炎免疫状态及免疫核糖核酸左旋咪唑疗效观察  

IMMUNOLOGIC STATUS IN VIRAL MYOCARDITIS: PRELIMINARY EVALUATION OF IMMUNO RIBO NUCLEIC ACID THERAPY

作　　者：郑义 包世宏[1] 俞国瑞[1] 郑道声 陈曙霞 陈诗书 

机构地区：[1]上海第二医学院附属第三人民医院 [2]上海第二医学院生物化学教研组

出　　处：《上海医学》1983年第1期12-15,共4页Shanghai Medical Journal

摘　　要：本文报告64例病毒性心肌炎的免疫状态,其中82例应用免疫核糖核酸(iRNA),17例应用左旋咪唑进行治疗观察;经iRNA治疗的病例,在治疗后3个月,结核菌素试验全部转为阳性,31/32患者其外周血液细胞免疫(羊红血球花瓣形成试验)增高,同时患者的体质亦普遍增强。iRNA组的总有效率为87.5%,左旋咪唑组为52.9%,两者有显著差异(P<0.01)。通过以上对病毒性心肌炎免疫功能的检测和两组药物治疗,作者认为提高细胞免疫力对今后病毒性心肌炎的治疗及阻断其演变为慢性病程之间的环节起着重要的作用。Immunologic status of 64 cases with viral myocarditis was studied.Among them thirty-two were treated with immuno-ribo-nucleic acid(iRNA),and 17 by levamisole.It was found that the OT test was converted into positive in all of the 32,and E-RFC increased in 31 out of 32 after a 3-mo course of iRNA treatment.Also the condition of patients in iRNA group was generally improved.The total effective rate of iRNA group was 87.5%,while that of levamisole group was 52.9%.Thus,there was significant difference between the two groups(p<0.01),The authors hold that a study of immunologic status in viral myocarditits and giving treatment to enhance the cellular immunologic function plays an important role in preventing progress toward chronicity of the disease.

关 键 词：IRNA 左旋咪唑 病毒性 免疫核糖核酸 特异性IRNA 心肌炎 心肌病 免疫状态 疗效观察 

分 类 号：R54[医药卫生—心血管疾病]